Supernus to Present at Cowen Health Care Conference in March
February 27 2017 - 4:33PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that the Company's management will present an
overview and update of the company and host investor meetings at
the Cowen & Company 37th Annual Health Care Conference.
Date: Wednesday, March 8, 2017Time: 10:40 a.m. ETPlace: The
Boston Marriott Copley Place, Boston, Mass.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
A live webcast of the presentation can be accessed by visiting
‘Events & Presentations’ in the Investors Section on the
Company's website at www.supernus.com. An archived replay of the
webcast will be available for 60 days on the Company's website
after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of Impulsive Aggression in ADHD patients and SPN-812 for
the treatment of ADHD.
CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024